4 September 2019 - Inotrem announced today that the U.S. FDA has granted fast track designation to nangibotide development program for the treatment of septic shock.
Nangibotide, which Phase IIb has just been cleared by the FDA, is a TREM-1 inhibitor peptide with the potential to restore appropriate inflammatory response, vascular function, and improve post septic shock survival.